A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

NCT02213263 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

394

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma

Interventions

BIOLOGICAL: PF-05280586
BIOLOGICAL: MabThera®

Sponsor

Pfizer